<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk factors for melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk factors for melanoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Risk factors for melanoma</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Category</td> <td class="subtitle1">Feature</td> <td class="subtitle1">Risk<br/> (given as relative risk [RR] with 95% CI unless indicated otherwise)</td> </tr> <tr class="divider_top"> <td class="divider_bottom" rowspan="6"><strong>Genotype</strong></td> <td>Xeroderma pigmentosum</td> <td>Approximately 1 in every 5 patients will develop melanoma<sup>[1]</sup></td> </tr> <tr> <td> <p>CDKN2A</p> Suspected in: <ul class="decimal_heading"> <li>families with multiple melanomas or pancreatic cancer </li> </ul> </td> <td> <p>35- to 70-fold<sup>[2]</sup></p> 67% lifetime risk</td> </tr> <tr> <td>CDK4 (very rare)</td> <td>Significantly elevated<sup>[3]</sup></td> </tr> <tr> <td>BRCA2 â€“ Familial breast and ovarian cancer</td> <td>2.58 (1.28-5.17)<sup>[4]</sup></td> </tr> <tr> <td> <p>MC1R</p> Suspected in: <ul class="decimal_heading"> <li>White people with red hair, freckling phenotype in family </li> </ul> </td> <td>2-3.5<sup>[2]</sup></td> </tr> <tr class="divider_bottom"> <td> <p>OCA2</p> Suspected in: <ul class="decimal_heading"> <li>Patients with a family history of albinism </li> </ul> </td> <td>Slightly increased risk, independent of phenotype</td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>Personal history of skin cancer</strong></td> <td>Melanoma</td> <td>1 to 8% of melanoma patients will be diagnosed with another melanoma<sup>[5]</sup></td> </tr> <tr class="divider_bottom"> <td>Nonmelanoma skin cancer (including actinic damage)</td> <td>4.28 (2.80-6.55)<sup>[6]</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="5"><strong>Family history</strong></td> <td>Any</td> <td>1.74 (1.41-2.14)<sup>[6]</sup></td> </tr> <tr> <td>Parent</td> <td> <p>2.40 (2.10-2.72)<sup>[7]</sup></p> <p>3.2 (2.6-3.9) for North American males*<sup>[8]</sup></p> 4.4 (3.5-5.2) for North American females</td> </tr> <tr> <td>Sibling</td> <td> <p>2.98 (2.54-3.47)<sup>[7]</sup></p> <p>3.2 (2.6-3.9) for North American males<sup>[8]</sup></p> 4.4 (3.5-5.2) for North American females<sup>[8]</sup></td> </tr> <tr> <td>2 first-degree relatives</td> <td>8.92 (4.25-15.31)<sup>[7]</sup></td> </tr> <tr class="divider_bottom"> <td>Parent with multiple primary melanomas</td> <td>61.78 (5.82-227.19)<sup>[7]</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="6"><strong>Atypical nevi</strong><sup>[9]</sup></td> <td>0</td> <td>1.00</td> </tr> <tr> <td>1</td> <td>1.45 (1.31-1.60)</td> </tr> <tr> <td>2</td> <td>2.10 (1.71-2.54)</td> </tr> <tr> <td>3</td> <td>3.03 (2.23-4.06)</td> </tr> <tr> <td>4</td> <td>4.39 (2.91-6.47)</td> </tr> <tr class="divider_bottom"> <td>5</td> <td>6.36 (3.80-10.33)</td> </tr> <tr> <td class="divider_bottom" rowspan="6"><strong>Common nevi</strong><sup>[9]</sup></td> <td>0 to 15</td> <td>1.00</td> </tr> <tr> <td>16 to 40</td> <td>1.47 (1.36-1.59)</td> </tr> <tr> <td>41 to 60</td> <td>2.24 (1.90-2.64)</td> </tr> <tr> <td>61 to 80</td> <td>3.26 (2.55-4.15)</td> </tr> <tr> <td>81 to 100</td> <td>4.74 (3.44-6.53)</td> </tr> <tr class="divider_bottom"> <td>101 to 120</td> <td>6.89 (4.63-10.25)</td> </tr> <tr> <td colspan="3"><strong>Phenotypic traits</strong><sup>[6]</sup></td> </tr> <tr> <td class="indent1" rowspan="3">Hair color</td> <td>Red versus dark</td> <td>3.64 (2.56-5.37)</td> </tr> <tr> <td>Blond versus dark</td> <td>1.96 (1.41-2.74)</td> </tr> <tr> <td>Light brown versus dark</td> <td>1.62 (1.11-2.34)</td> </tr> <tr> <td class="indent1">Freckles</td> <td>High versus low density</td> <td>2.10 (1.80-2.45)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Eye color</td> <td>Light (green, hazel, blue) versus dark</td> <td>Approximately 1.5</td> </tr> <tr> <td rowspan="4"><strong>Sun exposure</strong></td> <td>Intermittent</td> <td>2.35 (1.78-3.09)<sup>[6]</sup></td> </tr> <tr> <td>Chronic</td> <td>0.98 (0.85-1.12)</td> </tr> <tr> <td>Sunburn history</td> <td>2.02 (1.73-2.34)</td> </tr> <tr> <td>Tanning salon</td> <td>Ever versus never, 1.15 (1.00-1.31)<sup>[10]</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">* Estimates are for cases of familial melanoma.</div><div class="graphic_reference">References:

<ol>
<li>Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130:1018.</li>
<li>High WA, Robinson WA. Genetic mutations involved in melanoma: a summary of our current understanding. Adv Dermatol 2007; 23:61.</li>
<li>Goldstein AM, Struewing JP, Chidambaram A, et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000; 92:1006.</li>
<li>Easton D, The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91:1310.</li>
<li>Stam-Posthuma JJ, van Duinen C, Scheffer E, et al. Multiple primary melanomas. J Am Acad Dermatol 2001; 44:22.</li>
<li>Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41:2040.</li>
<li>Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 2003; 120:217.</li>
<li>Begg CB, Hummer A, Mujumdar U, et al. Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control 2004; 15:957.</li>
<li>Swerdlow AJ, English J, MacKie RM, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 1986; 292:1555.</li>
<li>The International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007; 120:1116.</li>
</ol>

From: Psaty EL, Scope A, Halpern AC, Marghoob AA. Defining the patient at high risk for melanoma. Int J Dermatol 2010; 49:362. <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2010.04381.x/abstract" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2010.04381.x/abstract</a>. Copyright Â© 2010 The International Society of Dermatology. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <a href="/cdn-cgi/l/email-protection#5b2b3e2936322828323435281b2c32373e2275383436" trget="_blank"><span class="__cf_email__" data-cfemail="324257405f5b41415b5d5c4172455b5e574b1c515d5f">[emailÂ protected]</span></a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href="http://www.onlinelibrary.wiley.com" target="_blank">www.onlinelibrary.wiley.com</a>).</div><div id="graphicVersion">Graphic 105397 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
